Compare LOMA & CGEM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LOMA | CGEM |
|---|---|---|
| Founded | 1926 | 2016 |
| Country | Argentina | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 999.4M |
| IPO Year | 2017 | 2020 |
| Metric | LOMA | CGEM |
|---|---|---|
| Price | $9.45 | $14.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 12 |
| Target Price | $14.30 | ★ $33.45 |
| AVG Volume (30 Days) | 462.9K | ★ 1.1M |
| Earning Date | 11-05-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.01% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $23.53 | N/A |
| Revenue Next Year | $10.89 | $280.38 |
| P/E Ratio | $187.97 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $7.87 | $6.73 |
| 52 Week High | $13.20 | $23.19 |
| Indicator | LOMA | CGEM |
|---|---|---|
| Relative Strength Index (RSI) | 40.88 | 42.25 |
| Support Level | $8.92 | $13.76 |
| Resistance Level | $12.10 | $16.31 |
| Average True Range (ATR) | 0.35 | 0.96 |
| MACD | -0.01 | 0.17 |
| Stochastic Oscillator | 12.00 | 42.19 |
Loma Negra Cia Industria Argentina SA is a cement producer in Argentina. The Group is engaged in the production and distribution of cement, masonry cement, concrete, limestone, and aggregates, operates a railway concession to provide transportation services, and is also engaged in the industrial waste recycling business. The company operates in five segments: Cement, masonry cement, and lime; Concrete; Rail services; Aggregates; and Others. The majority of its revenue derives from Cement, masonry cement, and lime segments.
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.